Author Archives: shanzhu

PHE investigating a novel variant of COVID-19

A new variant of the virus that causes COVID-19 (SARS-CoV-2) has been identified across the South East of England. The variant was identified due to Public Health England’s (PHE) proactive and enhanced monitoring following the increase in cases seen in Kent and London. The variant has been named ‘VUI – 202012/01’ (the first Variant Under Investigation […]

Alert Notification: New SARS-CoV-2 variant with multiple spike protein mutations

Date/Time:                           21 December 2020Incident/Event title/Name:    New SARS-CoV-2 variant with multiple spike protein mutationsNotification*:                        Alert          Warning          Activation         ExecutionFrom:                  […]

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

Report written by: Andrew Rambaut1, Nick Loman2, Oliver Pybus3, Wendy Barclay4, Jeff Barrett5, Alesandro Carabelli6, Tom Connor7, Tom Peacock4, David L Robertson8, Erik Volz4, on behalf of COVID-19 Genomics Consortium UK (CoG-UK)9. University of Edinburgh University of Birmingham University of Oxford Imperial College London Wellcome Trust Sanger Institute University of Cambridge Cardiff University MRC-University of […]

Statement of the WHO Working Group on COVID-19 Animal Models (WHO-COM) about the UK and South African SARS-CoV-2 new variants

Background The WHO-COM is an expert group of more than 150 scientists around the world with expertise in animal models of viral diseases. Since February 2020 the group has met weekly to discuss advances, foster collaborations, share resources and reagents and avoid duplication of effort. The WHO-COM met on 22 December 2020 to discuss current […]

Central Alerting System (CAS) alert

Originator: CMO Messaging From: CMO Messaging Issue date: 24-Dec-2020 18:20:50 This alert has been issued to: · NHS Regional Offices · NHS Foundation Trusts (England) – Medical Director · NHS Foundation Trusts (England) – Chief Executive · NHS Trusts (England) – Medical Director · NHS Trusts (England) – Chief Executive Other contacts · Independent Healthcare […]

COVID-19 (SARS-CoV-2): information about the new virus variant

The new variant transmits more easily than the previous one but there is no evidence that it is more likely to cause severe disease or mortality. Main points Data from whole genome sequencing, epidemiology and modelling suggest the new variant ‘VUI – 202012/01’ (the first Variant Under Investigation in December 2020) transmits more easily than […]

Products & Information Collection of SARS-CoV-2 (2019nCOV) spike-HV 69-70 Deletion mutation(ΔH69/ΔV70)

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-HV 69-70 Deletion mutation(ΔH69/ΔV70) Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-HV 69-70 Deletion mutation(ΔH69/ΔV70), which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies. GeneMedi codon-optimized […]

Spike(S1+S2)-N501Y mutation vectors and SARS-CoV-2(2019nCoV) Pseudotyped virus

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Spike-N501Y mutation Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-N501Y mutation, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies. SARS-COV-2 (2019nCOV) variant-N501Y mutation of Spike […]

Products & Information Collection of New variant SARS-COV-2 (2019nCOV) -UK B.1.1.7 lineage

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) B.1.1.7 lineage Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) B.1.1.7 lineage, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies. SARS-COV-2 (2019nCOV) B.1.1.7 lineage of Spike […]

P2-mutated Spike protein trimer variant (P2-mutant,S1/S2 cleavage site(furin cleavage sequence)-mutant,trimerization modified) vectors and SARS-CoV-2(2019nCoV) Pseudotyped virus

Products list of Spike trimer (P2-mutant, S1/S2 cleavage site (furin cleavage sequence)-mutant, trimerization modified) SARS-CoV-2 P2-mutated Spike protein trimer variant (P2-mutant, S1/S2 cleavage site(furin cleavage sequence)-mutant, trimerization modified) The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell […]